Airway subsensitivity with long acting β2-agonists. Is there cause for concern?

Drug Safety

Volumn 16, Issue 5, 1997, Pages 295-308

  Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; HISTAMINE; METHACHOLINE; SALMETEROL;

AIRWAY; ARTICLE; ASTHMA; BRONCHOSPASM; CORTICOSTEROID THERAPY; DRUG TOLERANCE; EXERCISE; GENETIC POLYMORPHISM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; RECEPTOR DOWN REGULATION;

EID: 0030907140     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716050-00002     Document Type: Article

References (60)

1. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6
2. Spitzer WO, Suissa S, Ernst B, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-6
3. Van Schayck CP, Van Herwarden CLA. Do bronchodilators adversely effect the prognosis of bronchial hyperresponsiveness? Thorax 1993; 48: 470-3
4. Cockeroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833-6
5. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413-9
6. 2-agonist terbutaline with an inhaled corticosteroid budesonide in newly detected asthma. N Engl J Med 1991; 325: 388-92
7. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma, dose response relationship. Pulm Pharmacol 1996; 9: 16-27
8. 2-agonists: time for reappraisal. Br J Clin Pharmacol 1995; 39: 109-18
9. Lipworth BJ, Grove A. Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol 1997; 43: 9-14
10. 2-agonists. Thorax 1996; 51: 1051-6
11. Gibson GJ, Greenacre JG, Conig P, et al. Use of exercise challenge to investigate possible tolerance to β-adrenoceptor stimulation in asthma. Br J Dis Chest 1978; 72: 199-206
12. Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554-8
13. 2-agonists in asthma. N Engl J Med 1992; 327: 1204-8
14. 2-agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995; 152: 1485-9
15. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma N Engl J Med 1992; 327: 1188-203
16. Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid-treated asthmatic subjects. Thorax 1996; 51: 1100-4
17. 2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993; 48: 112-24
18. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice-daily salmeterol in asthmatic patients Lancet 1995; 346: 210-6
19. Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatments. Am J Respir Crit Care Med 1995; 152: 1170-4
20. Verberne AAPH, Hop WCJ, Creyghton FBM, et al. Airway responsiveness after a single dose of salmeterol and during 4 months of treatment in children with asthma. J Allergy Clin Immunol 1996; 97: 938-46
21. Meijer CG, Postma DS, Molder PGH, et al. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med 1995; 152: 1887-92
22. Bhagat R, Kalra S, Swystun VA, et al. Rapid set of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-9
23. Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the broncho-protector effect of salmeterol. Chest 1996; 109: 953-6
24. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363-8
25. Giannini D, Carletti A, Dente FL, et al. Tolerance to the protective effect of salmeterol on allergen challenge. Chest 1996; 110: 1452-7
26. Gustafsson P, Ekstrom T, Forsstrom E, et al. Bronchial hyperresponsiveness and protection by salmeterol against bronchial cold air challenge during regular salmeterol treatment in steroid-treated asthmatics [abstract]. Eur Respir J 1995; 8: Suppl. 9: 455S
27. Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice-daily inhaled formoterol versus 4 times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622-5
28. Pearlman DS, Chervinsky P, Laforce C, et al. A comparison of salmeterol with albuterol in a treatment of mild to moderate asthma. N Engl J Med 1992; 327: 1420-5
29. Britton MG, Earnshaw JS, Palmer JBD. A 12-month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-7
30. Palmer JBD, Stuart AM, Shepherd GL, et al. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease: a three month comparison of the efficacy and safety of twice daily salmeterol (100μg) with salmeterol (50μg). Respir Med 1992; 86: 409-17
31. Lundback B, Rawlinson DW, Palmer JBD. Twelve-month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148-53
32. Steffensen I, Faurschou P, Riska H, et al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airways disease. Allergy 1995; 56: 657-63
33. Russell G, Williams DAG, Wella P, et al. Salmeterol xinofoate in children on high-dose inhaled steroids. Ann Allergy Asthma Immunol 1995; 75: 423-8
34. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher doses of corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-24
35. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-8
36. Lofdahl CG, O'Byrne PO, Barnes PJ, et al. The additive effects of budesonide and formoterol in reducing severe asthma exacerbations [abstract]. Proceedings of American Thoracic Society, San Francisco, May 1997. Am J Respir Crit Care Med. In press
37. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with formoterol in patients with asthma. Am J Med 1994; 97: 29-37
38. 2-adrenoreceptor responses after regular twice-daily treatment with formoterol dry powder in asthmatic patients. Thorax 1995; 50: 497-504
39. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not airways responses during prolonged therapy with high dose salbutamol in asthmatics. Am Rev Respir Dis 1989; 145: 586-92
40. Davis AO, Lefkowitz RJ. In vitro desensitisation of β-adrenergic receptors in human neutrophils. J Clin Invest 1983; 71: 565-71
41. Samuelson WN, Davis AO. Hydrocortisone induced reversal of β-adrenergic receptor uncoupling. Am Rev Respir Dis 1984; 130: 1023-6
42. 2-adrenergic receptors in vitro. J Clin Invest 1995; 96: 99-106
43. Hui KKD, Connelly ME, Taskin DP. Reversal of human lymphocyte β-adrenoceptor desensitisation by glucocorticoids Clin Pharmacol Ther 1982; 32: 566-71
44. Brodde O, Brinkmann M, Schemuth R, et al. Terbutaline-induced desensitisation of human lymphocytes β-adrenoceptor responsiveness by prednisolone and ketotifen. J Clin Invest 1985; 76: 1096-101
45. 2-bronchodilators. Eur J Clin Pharmacol 1988; 34: 145-50
46. 2-agonists. Am J Respir Crit Care Med 1996; 154: 1603-7
47. 2-adrenoceptor function in asthmatic patients. Chest 1996; 108: 343-7
48. 2-adrenoceptors in asthmatic patients [abstract]. Br J Clin Pharmacol 1996; 42: 659P
49. 2-adrenoceptor subsensitivity induced by formoterol [abstract]. Br J Clin Pharmacol 1996; 42: 654-5P
50. Tan KS, Grove A, McLean A, et al. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med. In press
51. Green SA, Turki J, Hall IP, et al. Implications of genetic variability of human β-adrenergic receptor structure. Pulm Pharmacol 1995; 8: 1-10
52. 2-adrenoceptor polymorphisms: are they clinically important? Thorax 1996; 51: 351-3
53. Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human β-adrenergic receptor impart distinct agonist-promotive regulatory properties. Biochemistry 1994; 33: 414-9
54. 2-adrenergic receptor genotypes on signal transduction in human airways smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25-33
55. Turki J, Green SA, Neuman KB, et al. Human lungs cell β-adrenergic receptors desensitise in response to in vivo administered β-agonist. Am J Physiol 1995; 269: 709-14
56. 2-adrenoceptor polymorphism determines susceptibility to bronchodilator desensitisation in asthmatics [abstract]. Thorax 1996; 51 Suppl. 3: A37
57. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamul in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-7
58. Finkelstein FN. Risks of salmeterol? [letter] N Engl J Med 1994; 331: 1314
59. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993; 87: 277-88
60. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 Suppl. 1: 1-22S